LSD analogues are close chemical relatives of LSD (lysergic acid diethylamide), a psychedelic drug, sold as research chemicals with no approved medical use. Interest centres on mood, anxiety, and longevity, but human evidence is thin and borrowed from LSD; longevity claims rest on early laboratory work. Risks: intense altered states lasting hours, and rises in heart rate and blood pressure. Product identity, dose, and long-term safety remain largely unmeasured. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Resting blood pressure | Below 120/80 mmHg | Acute rises follow LSD-type exposure |
| Resting heart rate | 50–70 beats per minute | Heart rate exceeded 100 in up to 25% after LSD |
| Corrected QT interval on electrocardiogram | Below 430 ms | Fatal arrhythmia reported with AL-LAD |
| Echocardiogram (heart ultrasound) | No more than trivial valve leakage; no valve thickening | 5-HT2B activation can scar valves with repeated exposure |
| Alanine and aspartate aminotransferases (liver enzymes) | Each below 25 U/L | Organ toxicity of analogues is unstudied |
| Anxiety and depression questionnaires | No established target for analogues; track change from own baseline (minimal symptoms are scores of 0–4) | Detects emotional worsening or improvement |
| Batch identity test (laboratory mass spectrometry) | One labelled compound; no unlisted lysergamides or impurities | Products are often misidentified |
Cadence: Baseline before any exposure; blood pressure and heart rate at baseline, hourly through the effect window and at resolution on each exposure day; questionnaires at 1 week, 4 weeks and 12 weeks; then electrocardiogram and liver enzymes every 6–12 months, with echocardiography added for repeated low-dose use